https://www.targetedonc.com/view/mirvetuximab-soravtansine-proves-safe-and-effective-in-fr--high-ovarian-cancer
Based on findings from the phase 3 SORAYA trial, mirvetuximab soravtansine gained FDA approval for the treatment of patients with folate receptor alpha-high platinum-resistant ovarian cancer.
Create an account
or login to join the discussion